Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129545 · ClinicalTrials.gov registry record · Phase 2
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation
A Phase 2 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 800
- Enrollment target
NCT00129545 is a Phase 2 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 800 participants.
The verdict
NCT00129545, a Phase 2 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 800 participants
- Enrollment target
Study Summary
This is a multi-center, prospective, randomized study, stratified by center, comparing the WATCHMAN device to long term warfarin therapy, demonstrating that the treatment arm is non-inferior to the control arm. This study was amended to allow for a non-randomized arm and increased enrollment.
Interventions
- DRUG Warfarin
- DEVICE WATCHMAN Left Atrial Appendage Closure Technology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2005-02 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129545
The ClinicalTrials.gov registry entry for NCT00129545 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT00129545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00129545 about?
NCT00129545 is a clinical study titled "WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation". This is a multi-center, prospective, randomized study, stratified by center, comparing the WATCHMAN device to long term warfarin therapy, demonstrating that the treatment arm is non-inferior to the control arm. This study was amended to allow for a non-randomized arm and increased enrollment.
What is the current status of trial NCT00129545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 800 participants. The study started on 2005-02. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00129545?
The interventions under investigation include: Warfarin (DRUG), WATCHMAN Left Atrial Appendage Closure Technology (DEVICE).
Who is sponsoring clinical trial NCT00129545?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.